

Organization:

In cooperation with:

Under the Auspices :



european society of digestive oncology

FORUM ON DIGESTIVE ONCOLOGY.

GASTRIC & ESOPHAGEAL MALIGNANCIES ACROSS DISCIPLINES

10 - 11

October

2025

Venue Royal Olympic
Hotel ATHENS

SCIENTIFIC

PROGRAM



From transformative medicines that take on the toughest challenges,
to biosimilar and supportive care outcome-enabling solutions we're

ADVANCING ALL ANGLES OF CARE

AMGEN

Oncology

ONCE-DAILY ORAL

LUMYKRAS®
(sotorasib) 240 mg tablets

LUMYKRAS ΠΧΠ



XGEVA®
(denosumab) injection
120 mg/1.7 mL vial

XGEVA ΠΧΠ



Vectibix®
(panitumumab)
100mg/5mL | 20mg/mL for injection

VECTIBIX ΠΧΠ



MVASI®
(bevacizumab)
Injection 100mg/vial & 400mg/vial

MVASI ΠΧΠ



Τρόπος διάθεσης:

Περιορισμένη ιατρική συνταγή από ειδικό ιατρό και παρακολούθηση κατά τη διάρκεια της αγωγής. Το προϊόν δεν είναι τιμολογημένο στην Ελλάδα, αναφέρεται προτεινόμενη τιμή 5.828 €

Τρόπος διάθεσης:

Περιορισμένη ιατρική συνταγή. Η διάγνωση και / ή η έναρξη της θεραπείας γίνεται σε νοσοκομείο και μπορεί να συνεχίζεται εκτός νοσοκομείου υπό νοσοκομειακή παρακολούθηση
Λ.Τ.: XGEVA INJ.SOL
120MG/1,7ML (70MG/ML)
BTx1VIAL: 277,08 €

Τρόπος διάθεσης:

Με περιορισμένη ιατρική συνταγή. Μόνο για νοσοκομειακή χρήση από γιατρό με κατάλληλη ειδίκευση και εμπειρία
Λ.Τ.: VECTIBIX C/S.SOL.IN
100MG/5ML VIAL BT x 1 VIAL
x 5 ML: 344,47 €
VECTIBIX C/S.SOL.IN
400MG/20ML VIAL BT x 1 VIAL
x 20 ML: 1.307,65 €

Τρόπος διάθεσης:

Περιορισμένη ιατρική συνταγή. Μόνο για νοσοκομειακή χρήση από γιατρό με κατάλληλη ειδίκευση και εμπειρία
Λ.Τ.: MVASI C/S.SOL.IN 25MG/ML
1 VIAL x 16ML: 714,67 €
MVASI C/S.SOL.IN 25MG/ML
1 VIAL x 4ML: 215,07 €

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα
συμπληρώνοντας την "ΚΙΤΡΙΝΗ ΚΑΡΤΑ"

Αναφέρετε κάθε ύποπτη ανεπιθύμητη ενέργεια σύμφωνα με το εθνικό σύστημα
ασφαλείας στο Τμήμα Ανεπιθύμητων Ενέργειών του Εθνικού Οργανισμού Φαρμάκων
(ΕΟΦ) Τηλ: +30 2132040337, με τη χρήση της Κίτρινης Κάρτας διαθέσιμη και στην
ιστοσελίδα του ΕΟΦ, www.eof.gr, www.kitrikarta.gr για έντυπη ή ηλεκτρονική υποβολή
ή εναλλακτικά στην AMGEN Ελλάς Φαρμακευτικά Ε.Π.Ε. Τηλ: +30 2103447000

GRC-511-0225-80001

Πριν τη συνταγογράφηση συμβουλευθείτε
τις Περιλήψεις Χαρακτηριστικών των
Προϊόντων, που είναι διαθέσιμες παραπάνω.

AMGEN HELLAS ΕΠΕ

Αγ. Κωνσταντίνου 59-61

Green Plaza, κτίριο Γ, 15 124 Μαρούσι

Τηλ: 210 3447000 - Fax: 210 3447050

Email: info@amgen.gr, www.amgen.gr



WELCOME MESSAGE FROM THE ORGANIZING COMMITTEE

Dear Colleagues,

Following the success of our previous Forum on Gastrointestinal Oncology, dedicated to Hepatobiliary & Pancreatic malignancies, it is our great pleasure to welcome you once again to Athens for the subsequent meeting of this series. This year, the focus will turn to **Gastroesophageal malignancies**, a field equally demanding and rapidly evolving, where multidisciplinary collaboration is essential to improving patient outcomes.

The **Hellenic Society of Gastrointestinal Oncology together with the Johannes Gutenberg University of Mainz** are proud to organize this meeting, bringing together distinguished speakers from **Germany, Switzerland, Israel, and Greece**, covering a broad spectrum of disciplines. The University of Mainz, with its long academic tradition and internationally recognized research excellence, continues to be a pillar of innovation and knowledge in oncology.

The program will be based entirely on **case discussions** across multiple clinical scenarios, designed to address the complexities of real-world practice. In addition, **hot topic sessions** will highlight advances in **molecular oncology, novel biomarkers, and emerging treatment strategies**, ensuring that participants are updated on the forefront of innovation.

Over two days, colleagues from **surgery, medical oncology, gastroenterology, gastroenterologist oncology, radiation oncology, radiology, interventional radiology, pathology, nuclear medicine, genetics, cardiology, nutrition science, speech and language therapy, and supportive care** will contribute to an interactive program emphasizing practical insights, state-of-the-art science, and collaborative problem solving.

Athens, with its unique blend of history and modern vibrancy, once again provides the ideal backdrop for our exchange of knowledge and experience. We warmly invite you to join us on **October 10 & 11, 2025**, at the Royal Olympic Hotel, to continue building on the strong foundations of our growing forum series.

On behalf of the organizing committee, we extend our sincere welcome and look forward to another stimulating and fruitful conference.

Yours sincerely,

Conference Co-Chairs

Georgios Lypas - Medical Oncologist,

Markus Moehler - Gastroenterologist Oncologist,

Thomas Thomaidis - Gastroenterologist, HSGO



I don't
want a
fairy
tale

I need everything
you've got



Για περισσότερες πληροφορίες απευθυνθείτε στην Εταιρεία
Η Περιήληψη των Χαρακτηριστικών του Προϊόντος είναι στη διάθεσή σας.
Αναζητήστε την από εκπρόσωπο της εταιρείας ή στον υπεύθυνο δόσημο
<https://www.lilly.gr/landing-pages/cyramza/> ή σκανάρετε τον κωδικό QR

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»



ΦΑΡΜΑΣΕΡΒ - ΛΙΛΛΥ Α.Ε.Β.Ε.

15ο χλμ. Εθνικής Οδού Αθηνών-Λαμίας, 14564 Κηφισιά ΤΗΛ.: 210 6294600 Fax: 210 6294610

Για παραγγελίες: ΤΗΛ.: 210 6294629 Fax: 210 6294630 e-mail: orders@lilly.gr www.lilly.gr

Συνδεθείτε με τη ΦΑΡΜΑΣΕΡΒ-ΛΙΛΛΥ
στα κοινωνικά δίκτυα



CYR_GC_A4v_05/2023



FORUM ON DIGESTIVE ONCOLOGY.

GASTRIC & ESOPHAGEAL MALIGNANCIES ACROSS DISCIPLINES

10 - 11
October
2025

Venue Royal Olympic
Hotel ATHENS



COMMITTEES

Organizing Committee

Co-Chairs:

Lypas Georgios
Moehler Markus
Thomaidis Thomas

Members:

Fostira Florentia
Koutroumpi Maria
Lyros Orestis
Michailidou Maria
Papalois Apostolos
Stamataki Asteria
Vogiatzis Merkourios

Scientific Committee

Co-Chairs:

Avgoustidou Maria
Papaxoinis Georgios

Members:

Brenner Baruch
Marquardt Jens
Oestereicher Gabrielle
Pagkratis Spyridon
Petrowski Katja
Shmanko Kateryna
Sivanathan Visvakanth
Tsirlis Theodoros
Weinmann Arndt

ΕΓΚΕΚΡΙΜΕΝΟ ΑΠΟ ΤΟΝ ΕΜΑ: ως μονοθεραπεία για ενήλικες ασθενείς οι οποίοι έχουν υποβληθεί προηγουμένως σε διαθέσιμες τυπικές θεραπείες¹

 **Fruzaqla®** ▼
(fruquintinib) capsules

Επαναπροσδιορίστε την επιβίωση

Η πρώτη στοχευμένη θεραπεία στον mCRC ανεξαρτήτως μεταλλάξεων^{1,3}

Το FRUZAQLA ενδείκνυται:

Το FRUZAQLA ως μονοθεραπεία ενδείκνυται για τη θεραπεία του μεταστατικού ορθοκολικού καρκίνου (mCRC) σε ενήλικες ασθενείς οι οποίοι έχουν υποβληθεί προηγουμένως σε διαθέσιμες τυπικές θεραπείες, συμπεριλαμβανομένης της χημειοθεραπείας με βάση την φθοριοπυριμιδίνη, την οξαλιπλατίνη και την ιρινοτεκάνη, παράγοντες αντι-VEGF και παράγοντες αντι-EGFR, και οι οποίοι έχουν παρουσιάσει πρόοδο νόσου ή είχαν δυσανεξία σε θεραπεία είτε με τριφλουριδίνη/τιπιρασίλη είτε με ρεγοραφενίμη.

Βιβλιογραφικές παραπομπές:

1. FRUZAQLA®. Περίληψη χαρακτηριστικών του προϊόντος.
2. Dasari A, Lonardi S, Garcia-Carbonero R, et al; FRESCO-2 Study Investigators. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402(10395):41-53.
3. Li J, Qin S, Xu R, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA. 2018;319(24):2486-2496.

Περιορισμένη ιατρική συνταγή από ειδικό ιατρό και παρακολούθηση κατά τη διάρκεια της αγωγής.

FRUZAQLA Tabs, 5 mg/Tab, BT x 21: Ενδεικτική Τιμή Παραγωγού 5.652,21€
FRUZAQLA Tabs, 1 mg/Tab, BT x 21: Ενδεικτική Τιμή Παραγωγού 1.420,15€

Ενδεικτική τιμή πώλησης/συσκευασία [με βάση την ισχύουσα νομοθεσία αναφορικά με τους κανόνες τιμολόγησης και ανατιμολόγησης φαρμάκων αναφοράς εντός της περιόδου προστασίας των δεδομένων τους (on patent)].

Πριν τη συνταγογράφηση συμβουλευθείτε την Περίληψη Χαρακτηριστικών του Προϊόντος ΕΔΩ.

▼ Το φάρμακο αυτό τελεί υπό συμπληρωματική παρακολούθηση. Αυτό θα επιτρέψει το γρήγορο προσδιορισμό νέων πληροφοριών ασφάλειας. Ζητείται από τους επαγγελματίες υγείας να αναφέρουν οποιοδήποτε πιθανολογούμενες ανεπιθύμητες ενέργειες. Βλ. παράγραφο 4.8 της ΠΧΠ για τον τρόπο αναφοράς ανεπιθύμητων ενεργειών.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή
και Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες
για ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Κάτοχος άδειας Κυκλοφορίας
Takeda Pharmaceuticals International AG Ireland
Τοπικός Αντιπρόσωπος Takeda Ελλάς Α.Ε.
Green Plaza, Κτίριο Β, Αγ. Κωνσταντίνου 59-61, 151 24 Μαρούσι
Τηλ. κέντρο: 2106387800, Fax: 2106387801, www.takeda.gr

Πριν από τη συνταγογράφηση του
FRUZAQLA, συμβουλευτείτε την
Περίληψη Χαρακτηριστικών του
Προϊόντος (Π.Χ.Π.), η οποία είναι
διαθέσιμη μέσω του κώδικα QR.



EXA/GR/FRZ/0006, 01/25



SCIENTIFIC PROGRAM

Friday, October 10th, 2025

08:30-09:00	Registrations
09:00-10:00	Oral Presentations
	Moderators: T. Thomaidis, O. Lyros
10:00-10:45	Case 1 : Early Esophageal Adenocarcinoma (cT1N0)
	Moderators: T. Thomaidis, O. Lyros, J. Marquardt
	Presenter: T. Thomaidis
	Invited Commentator: Surgery - D. Schizas
	Discussants:
	Gastroenterology: T. Thomaidis, V. Sivanathan
	Pathology: K. Pavlou
	Surgery: S. Moenig
	Nutrition & Dietetics: A. Stamataki
	Discussion Points:
	Endoscopic resection criteria (size, depth, LVI)
	Histopathologic risk factors for nodal disease
	Accurate T1 staging: EUS vs MRI
	Minimally invasive esophagectomy outcomes
	Ablation of residual Barrett’ s mucosa
	Surveillance endoscopy & imaging schedule
	Nutrition after EMR/ESD vs surgery
	Impact of obesity & reflux control
	T. Thomaidis
	K. Pavlou
	V. Sivanathan
	S. Moenig
	T. Thomaidis
	V. Sivanathan
	A. Stamataki
	S. Moenig

Fulvestrant / Innovis

Fulvestrant

Abinone®

Abiraterone Acetate

Inepitant®

Aprepitant

Dexacort®

Dexamethasone



INNOVIS PHARMA A.E.B.E.

Λεωφ. Κηφισίας 44

Μαρούσι, 15125

T:+30 2162005600

F:+30 2106664804

www.innovispharma.gr

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή
και Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «**Κίτρινη Κάρτα**»

Πριν τη συνταγογράφηση συμβουλευτείτε την
ΠΧΠ του προϊόντος η οποία είναι διαθέσιμη από
την εταιρεία εφόσον ζητηθεί

ΑΔΠ-ΑΦΟ4-0625

DEXACORT® SOLU.TAB 8MG/TAB X 30 tabs σε Alu-Alu blister
Τρόπος διάθεσης: Με ιατρική συνταγή
Λιανική Τιμή: 111,04€ Δ.Τ.5/2025

DEXACORT® SOLU.TAB 40MG/TAB BT X 10 tabs σε Alu-Alu blister
Τρόπος διάθεσης: Φαρμακευτικό προϊόν για το οποίο απαιτείται περικομμένη
ιατρική συνταγή από ειδικό ιατρό & παρακολούθηση κατά τη διάρκεια της αγωγής
Λιανική τιμή: 249,08€ Δ.Τ.5/2025

FULVESTRANT/INNOVIS INJ.SO.PFS 250MG/5ML BT X 2 PFS.YR (GLASS-TYPE 1) X 5 ML
+ 2 BEANES AZΘΑΞΙΑΣ (BD Safety Glide)

Τρόπος διάθεσης: Με ιατρική συνταγή
Λιανική Τιμή: 264,51 € Δ.Τ. 5/2025

ABINONE® F.C.TAB 500MG/TAB BT X (60 X 1) TAB SE BLISTER (PVC/PVDC/AL) - UNIT DOSE
Τρόπος διάθεσης: Με ιατρική συνταγή
Λιανική Τιμή: 1554,33 € Δ.Τ. 5/2025

INEPITANT® CAPS 125MG/CAP BTx1 cap x 125 + 2 cap x 80MG σε blisters
(OPA/ALU/PVC/αλουμινίου)

Τρόπος διάθεσης: Με ιατρική συνταγή
Λιανική Τιμή: 26,81 € Δ.Τ. 5/2025



Friday, October 10th, 2025

10:45-11:30

Case 2: Locally Advanced Cervical Esophageal (cT3N1)

Moderators: **L. Mueller, E. Petinellis**

Presenter: **N. Watanabe**

Invited Commentator: **Surgery - T. Liakakos**

Discussants

Radiation Oncology: E. Petinellis

Medical Oncology: T. Tegos

Surgery: A. Charalambopoulos

Nutrition & Dietetics: A. Stamatakis

Speech & Language Therapy: I. Papathanasiou

Discussion Points:

Definitive CRT vs surgery evidence

Radiation dose & IMRT planning

Cisplatin /5-FU vs taxol/carboplatin regimens

Toxicity management (mucositis, strictures)

Salvage surgery indications/morbidity

Induction chemotherapy role

Post-CRT checkpoint inhibitors

Nutritional support (PEG vs NGT)

PET-CT for response adapted decisions

Rehabilitation of dysphagia & voice



E. Petinellis

E. Petinellis

T. Tegos

E. Petinellis

A. Charalambopoulos

T. Tegos

T. Tegos

A. Stamatakis

E. Petinellis

I. Papathanasiou

11:30-11:45

Coffee Break

11:45-12:00

Hot topics

Moderators: **G. Lypas, C. Veros**

ctDNA & Novel Biomarkers

C. Veros



OPDIVO[®] + **YERVOY[®]** *(nivolumab)* *(ipilimumab)*

Πριν τη συνταγογράφηση συμβουλευτείτε την Περίληψη Χαρακτηριστικών Προϊόντος που διατίθεται από τον ΚΑΤΟΧΟ ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ κατόπιν αιτήσεως

 **Bristol Myers Squibb[®]**

Bristol-Myers Squibb A.E.
 Αττικής 49-53 & Προποντίδος 2, Τ.Κ. 152 35 Βριλήσσια, Αττική
 ΤΘ 63883 - Βριλήσσια, Τ.Κ. 152 03, Αττική
 Τηλ. 210 6074300 & 210 6074400, Φαξ 210 6074333
 Αριθμός Γ.Ε.ΜΗ 7453601000

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
 Αναφέρετε ΟΛΑ τα φάρμακα
 Συμπληρώνοντας την "ΚΙΤΡΙΝΗ ΚΑΡΤΑ"
 Ελλάδα: <https://www.kitrinakarta.gr>
 Κύπρος: <https://www.kitrinakarta.gov.cy>



Friday, October 10th, 2025

12:00-12:45

Case 3: Locally Advanced GEJ Adenocarcinoma
(cT3N2, Siewert II)

Moderators: **B. Brenner, O. Lyros**

Presenter: **O. Lyros**

Invited Commentator: **Surgery - T. Liakakos**

Discussants:

Medical Oncology: B. Brenner

Surgery: A. Charalambopoulos, S. Moenig

Nutrition & Dietetics: A. Chremou

Radiation Oncology: E. Petineli

Pathology: D. Papaioannou

Discussion Points:

Peri-op FLOT vs CROSS CRT

Staging laparoscopy & PET-CT

Pre-treatment nutrition

Transhiatal vs transthoracic resection

Downstaging radiotherapy considerations

Pathologic CR predictors

Peri-op adjuvant based on Mandard TRG

Managing anastomotic leaks

Molecular profiling (HER2, MSI, CLDN18.2)

Survivorship & QoL follow-up

B. Brenner

A. Charalambopoulos

A. Chremou

S. Moenig

E. Petinellis

D. Papaioannou

D. Papaioannou

S. Moenig

B. Brenner

A. Charalambopoulos



Akynzeo®

netupitant/palonosetron

Ένα καψάκιο περιέχει 300 mg netupitant και 0,5 mg palonosetron



Galenica

Αθήνα: Ελευθερίας 4, Κηφισιά 14564, τηλ.: 210 5281700
Τμήμα Φαρμακοεπαγρύπνησης τηλ: 210 5281700
e-mail: pn@galenica.gr • www.galenica.gr

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Συμβουλευτείτε
την Περίληψη
Χαρακτηριστικών του
Προϊόντος
Akynzeo® SmPC



HELSINN

Building quality cancer care together

Διανέμεται κατόπιν αδείας
της Helsinn Healthcare S.A, Ελβετία

innohep®

tinzaparin sodium



Χορηγείται με ιατρική συνταγή.
Για πλήρεις συνταγογραφικές πληροφορίες επικοινωνήστε
με την LEO Pharmaceutical Hellas S.A.

Για το ισχύον δελτίο τιμών
των φαρμάκων της LEO Pharma
σκανάρετε εδώ



LEO Pharmaceutical Hellas S.A
Παπανικολή 22Α, 15232, Χαλάνδρι
Τηλ: 212 222 5000
contact@leo-pharma.com
ap. FEMH 117058301000



Advancing the care of
patients with thrombosis

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

© LEO Pharma copyright - GR_inn_adv_Nov_2024- MAT-71106.
All LEO Pharma trademarks mentioned belong to the LEO Pharma Group.



Friday, October 10th, 2025

14:30-15:15

Case 5: Stage II Gastric Adenocarcinoma -
Peri-operative Chemotherapy

Moderators: **B. Brenner, O. Lyros**

Presenter: **K. Shmanko**

Invited Commentator: **Surgery - E. Delaportas**

Discussants:

Medical Oncology: B. Brenner

Surgery: O. Lyros

Radiation Oncology: G. Kritselis

Nutrition & Dietetics: A. Chremou

Discussion Points:

- Peri-op FLOT vs adjuvant CRT evidence
- D2 lymphadenectomy patterns
- Chemotherapy toxicity management
- Mid-therapy imaging for response
- ERAS peri-op recovery protocols
- Rx role for positive margins
- Enteral/jejunostomy nutrition
- Molecular markers guiding adjuvant
- Preventing post-op complications
- Long-term surveillance schedule



- B. Brenner**
- O. Lyros**
- B. Brenner**
- O. Lyros**
- O. Lyros**
- G. Kritselis**
- A. Chremou**
- B. Brenner**
- O. Lyros**
- B. Brenner**

DON'T MAKE THEM WAIT.



Use CABOMETYX® early in all progressive NETs patients¹

Get ahead with significant efficacy gains
proven in a broad patient population*²



Keep time on their side²

References: 1. CABOMETYX® Summary of Product Characteristics. 2. Chan JA, et al. N Engl J Med. Published online September 16, 2024. *after prior systemic therapy

IPSEN MON. ΕΠΕ

ΑΓΙΟΥ ΔΗΜΗΤΡΙΟΥ 63, 174 56 ΑΛΙΜΟΣ, ΑΘΗΝΑ, ΤΗΛ.: 210 9843324

E-mail: ipsenepe@ipsen.com

www.ipsen.com/greece

Τηλέφωνα φαρμακοεπαγρύπνησης: 210 98 43 324, 210 98 58 930

ΔΤΦ: 04/01/2025

CABOMETYX F.C.TAB 20MG/TAB Φιάλη (HDPE) x 30 tabs: 4215,05€

CABOMETYX F.C.TAB 40MG/TAB Φιάλη (HDPE) x 30 tabs: 4215,05€

CABOMETYX F.C.TAB 60MG/TAB Φιάλη (HDPE) x 30 tabs: 4215,05€



Περίληψη Χαρακτηριστικών
Προϊόντος CABOMETYX®
Ημ. αναθεώρησης κειμένου,
23 Ιουλίου 2025


CABOMETYX®
(cabozantinib) tablets

CMK-GR-000784/SEP 2025

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

 **IPSEN**



Friday, October 10th, 2025

15:15-16:00

Case 6: Conversion Therapy for Initially Unresectable Gastric Cancer

Moderators: S. Moenig, T. Tzanninis

Presenter: K. Shmanko

Invited Commentator: Surgery - I. Dimitriou

Discussants:

Surgery: S. Moenig

Medical Oncology: K. Shmanko, M. Moehler

Radiation Oncology: G. Kritselis

Nutrition & Dietetics: D. Karagiannis

Discussion Points:

Criteria for unresectability	S. Moenig
Induction chemotherapy (FOLFOXIRI)	K. Shmanko
Chemoradiation for downstaging	G. Kritselis
HER2-targeted therapy integration	K. Shmanko
Immunotherapy in conversion setting	M. Moehler
CT monitoring of resectability	S. Moenig
Surgical approach after response	S. Moenig
Nutrition with gastric outlet stenting	D. Karagiannis
Curative vs palliative intent dialogue	S. Moenig
Handling positive peritoneal cytology	S. Moenig

16:00-16:15

Coffee Break

16:15-16:30

Hot topics

Moderators: B. Brenner

Resilience & Posttraumatic Growth

K. Petrowski



Friday, October 10th, 2025

16:30-17:15

Case 7: Hereditary Diffuse Gastric Cancer (CDH1 Mutation)

Moderators: **F. Fostira, G. Lypas**

Presenter: **F. Fostira**

Discussants:

Genetics: F. Fostira

Gastroenterology: V. Sivanathan

Medical Oncology: B. Brenner

Discussion Points:

Testing criteria & genetic counseling

F. Fostira

Limitations of endoscopic surveillance

V. Sivanathan

Timing of prophylactic gastrectomy

F. Fostira

Cascade testing of relatives

F. Fostira

Breast cancer risk & screening

G. Lypas

Fertility & PGD considerations

F. Fostira

17:15-18:00

Case 8: Oligometastatic Liver-Only Gastric Metastasis

Moderators: **M. Moehler, G. Tzimas**

Presenter: **E. Litina**

Discussants:

Surgery: S. Moenig, G. Tzimas

Medical Oncology: M. Moehler

Interventional Radiology: M. Glynos

Discussion Points:

Definition of oligometastasis

S. Moenig

Hepatectomy vs MWA vs SBRT

G. Tzimas

Timing with systemic therapy

M. Moehler

Portal vein embolization

M. Glynos

IR coordination & logistics

M. Glynos

ctDNA prognostic value

M. Moehler



Friday, October 10th, 2025

18:00-18:30

Hot topics

Moderators: **K. Konstantinidis, J. Marquardt**

Robotic Surgery in Upper GI Malignancies

P. Grimmer

18:30-19:00

Opening Ceremony

Chairs: **G. Lypas, T. Thomaidis**

Greetings

Opening Lecture

Upper GI Cancers: international and multidisciplinary collaborations empower long term survivorship

M. Moehler





Saturday, October 11th, 2025

08:00-09:00

Oral Presentations

Moderators: **M. Avgoustidou, G. Lypas**

09:00-09:45

Case 9: Metastatic HER-2 Positive Gastric Adenocarcinoma

Moderators: **M. Avgoustidou, G. Lypas**

Presenter: **N. Watanabe**

Discussants:

Medical Oncology: P. Thuss-Patience, M. Avgoustidou

Nuclear Medicine: M. Vogiatzis

Cardiology: P. Danias, P. Koutrolou

Gastroenterology: M. Malamatenios

Discussion Points:

ToGA & DESTINY-Gastric data

Trastuzumab with FOLFOX vs CAPOX

T-DXd in second line - need for repeat biopsy?

PET-CT for response assessment

Cardiotoxicity surveillance

Local therapy for bleeding lesions

Nutrition & symptom palliation

Clinical trial enrollment

End-of-life planning & support

P. Thuss-Patience

P. Thuss-Patience

P. Thuss-Patience

M. Vogiatzis

P. Danias, P. Koutrolou

M. Malamatenios

M. Avgoustidou

P. Thuss-Patience

M. Avgoustidou



Saturday, October 11th, 2025

09:45-10:30

Case10: MSI-H Metastatic Gastric Cancer -
Immunotherapy Frontline

Moderators: **H. Grabsch, G. Lypas**

Presenter: **G. Papaxoinis**

Discussants:

Medical Oncology: **M. Moehler, G. Papaxoinis, G. Lypas**

Pathology: **H. Grabsch**

Gastroenterology: **M. Malamatenios**

Discussion Points:

Pembrolizumab vs chemo-IO evidence

M. Moehler

Hyperprogression & early imaging

G. Papaxoinis

Pseudoprogression management

M. Moehler

TIL & PD-L1 biomarkers

H. Grabsch

Sequencing post-IO progression

G. Papaxoinis

Lynch syndrome genetic work-up

G. Lypas

ICI-associated colitis

M. Malamatenios

Long-term responders follow-up

M. Moehler

10:30-11:00

Hot topics

Moderators: **H. Grabsch, T. Thomaidis**

New Biomarkers & EU Trials

M. Moehler

11:00-11:15

Coffee Break



Saturday, October 11th, 2025

11:15-12:00

Case1 1 : Gastric Cancer with Peritoneal Dissemination - HIPEC

Moderators: **G. Papaxoinis, A. Perrakis, K. Stamou**

Presenter: **K. Stamou**

Invited Commentator: **Surgery - D. Schizas**

Discussants:

Surgery: K. Stamou, A. Perrakis

Medical Oncology: G. Papaxoinis

Discussion Points:

- PCI scoring & selection
- Cytoreduction timing with chemotherapy
- HIPEC drug choices (cisplatin + doxorubicin)
- PIPAC as alternative
- Morbidity & QoL outcomes
- Adjunct immunotherapy options
- Monitoring via CT vs laparoscopy
- Ongoing clinical trials

- K. Stamou**
- G. Papaxoinis**
- G. Papaxoinis**
- K. Stamou**
- A. Perrakis**
- G. Papaxoinis**
- A. Perrakis**
- K. Stamou**





Saturday, October 11th, 2025

12:00-12:45

Case12: CLDN18.2-Targeted Therapy in Metastatic Gastric Cancer

Moderators: **M. Moehler**

Presenter: **N. Watanabe**

Discussants:

Medical Oncology: E.S. Tripodaki, G. Papaxoinis, M. Moehler

Pathology: H. Grabsch

Discussion Points:

SPOTLIGHT & GLOW trial data

E.S. Tripodaki

IHC scoring methodology

H. Grabsch

Sequencing with HER2 & PD-L1 therapies

E.S. Tripodaki

Managing CINV & GI toxicity

G. Papaxoinis

Radiologic vs biomarker response assessment

G. Papaxoinis

Combination strategies (IO + chemo)

E.S. Tripodaki

Next-gen bispecifics pipeline

M. Moehler

12:45-13:15

Hot topics

Moderator: **E. Eleftheriadis, L. Mueller**

AI Diagnostics

H. Grabsch

13:15-14:30

Lunch Break



Saturday, October 11th, 2025

14:30-15:15

Case13: Refractory GIST after Imatinib & Sunitinib

Moderators: C. Veros, A. Weinmann

Presenter: K. Shmanko

Invited Commentator: Nuclear Medicine - T. Pipikos

Discussants:

Medical Oncology: A. Weinmann, C. Veros

Surgery: N. Vassos

Nuclear Medicine: M. Vogiatzis

Discussion Points:

- Regorafenib & ripretinib evidence
- Molecular re-profiling importance
- Surgery for limited progression
- Early PET metabolic response
- Hand-foot syndrome management
- IO trial opportunities

- A. Weinmann
- C. Veros
- N. Vassos
- M. Vogiatzis
- A. Weinmann
- C. Veros





Saturday, October 11th, 2025

15:15-16:00

Case1 4: Frail Elderly Stage IV Gastric Cancer - Geriatric Focus

Moderators: **M. Avgoustidou, D. Matthaïos**

Presenter: **M. Avgoustidou**

Invited Commentator: **Geriatric Oncology - A. Karampeazis**

Discussants:

Medical Oncology: M. Avgoustidou, D. Matthaïos, O. Sismanidou

Nutrition & Dietetics: A. Kontou

Discussion Points:

Comprehensive geriatric assessment (CGA) tools

De-escalated chemo vs single-agent immunotherapy

Dose attenuation & extended intervals

Prophylactic G-CSF/ESA support

Sarcopenia management (exercise, nutrition)

Advance directives & goals-of-care discussions

Renal & marrow toxicity surveillance

M. Avgoustidou

O. Sismanidou

D. Matthaïos

D. Matthaïos

A. Kontou

M. Avgoustidou

O. Sismanidou

16:00-16:15

Coffee Break

16:15-16:30

Hot topics

Moderators: **M. Moehler, A. Stamataki**

Exercise as key component in cancer patient management

I. Arnaoutis



Saturday, October 11th, 2025

16:30-17:15

Case15: T3N1M1 Gastric Cancer, Disseminated Carcinomatosis, Post-Anastomosis Rupture

Moderators: **M. Avgoustidou, O. Lyros**

Presenter: **M. Avgoustidou**

Invited Commentator: **Surgery- D. Schizas**

Discussants:

Surgery: O. Lyros

Medical Oncology: M. Avgoustidou

Radiology: M. Staikou

Discussion Points:

- Importance of diagnostic laparoscopy & role of surgeon
- Established and emerging biomarkers
- Systemic treatment options
- The approach of the radiologist
- Cross-collaboration across specialties
- Surgical commentary

- O. Lyros**
- M. Avgoustidou**
- M. Avgoustidou**
- M. Staikou**
- O. Lyros**
- D. Schizas**

17:15-17:45

Onscreen Updates

Open discussion: University of Mainz, HSGO



FORUM ON DIGESTIVE ONCOLOGY.

GASTRIC & ESOPHAGEAL MALIGNANCIES ACROSS DISCIPLINES

10 - 11
October
2025

Venue Royal Olympic
Hotel ATHENS



FACULTY

Arnaoutis Giannis	MSc, PhD Assistant Professor in Sports Nutrition Department of Nutrition & Dietetics School of Health Sciences & Education, Harokopio University of Athens
Avgoustidou Maria	Medical Oncologist, Athens Medical Group
Brenner Baruch	Head, Department of Oncology, Davidoff Cancer Center Rabin Medical Center, Beilinson Hospital
Charalambopoulos Alexandros	MD,MSc,PhD,MRCS(Eng),FRCS(Gen Surg - Upper GI
Chremou Aikaterini	Clinical Nutrition Expert Head Clinical Dietitian-Nutritionist, MS,HCP, GRESPEN, «MITERA» General, Maternity & Children's Hospital S.A., HHG
Danias Petros	MD, PhD, FACC, FESC, Cardiologist, Head of the Magnetic Tomography Department, «HYGEIA» Hospital
Delaportas Dionysios	Associate Professor Of Surgery, National and Kapodistrian University of Athens
Dimitriou Ioannis	MD PHD Director General Surgical Clinic , Oncological & Robotic Surgery, Athens Medical Center
Eleftheriadis Eleftherios	MD, PhD, MBA, IFCAP Managing Director ISTODIEREVNITIKI SA Histopathology Laboratories
Fostira Florentia	Assistant Researcher, Clinical Laboratory Geneticist
Glynos Michalis	Interventional Radiologist, Co-Chief of Interventional Radiology and peripheral vasculature Department, «Metropolitan General» Hospital
Grabsch Heike	Professor in Gastrointestinal Pathology Leeds Institute of Cancer and Pathology University of Leeds, UK and Department of Pathology Maastricht University Medical Centre, Netherlands
Grimminger Peter Phillip	Surgeon, Johannes Gutenberg University Mainz
Karagiannis Dimitrios	Director, Department of Clinical Nutrition, «O Evaggelismos» Hospital Athens , Greece
Karampeazis Athanasios	MD, PhD, Pathologist - Oncologist, Director of Oncology Clinic 401, General Hospital & External Associate, «Henry Dunant» Hospital Center
Konstantinidis Konstantinos M.	MD, PhD, FACS, MAMSE Scientific Medical Director & Chairman of General, Oncologic,Laparoscopic, & Robotic Surgery, Athens Medical Center. Clinical Professor of Surgery, European University of Cyprus, School of Medicine Adjunct Professor of Surgery, Ohio State University, USA. Member, Academy of Master Surgeon Educators, American College of Surgeons, MAMSE. Governor, American College of Surgeons, Greek Chapter(ACS-GC). Past President, Clinical Robotic Surgery Association, (CRSA). American Board of Surgery Certified
Kontou Niki	Director, Department of Nutrition & Dietetics, Saint Savvas Cancer Hospital, Athens, Greece. Post Doct Researcher Laboratory of Clinican Nutrition, University of Thessaly, Greece



FORUM ON DIGESTIVE ONCOLOGY.

GASTRIC & ESOPHAGEAL MALIGNANCIES ACROSS DISCIPLINES

10 - 11
October
2025

Venue Royal Olympic
Hotel ATHENS



FACULTY

Koutrolou Paraskevi	MD, FACC, Cardiologist, Scientific Associate, «HYGEIA»
Kritselis Georgios	Radiotherapist, Oncologist, Athens Medical Center
Liakakos Theodore D.	Emeritus Professor of Surgery NKUA
Litina Eleni	General Surgeon
Lypas Georgios	Oncologist, Director of Department of Genetic Oncology, «HYGEIA» Hospital
Lyros Orestis	MD, PhD, FACS, FEBS/MIS Assistant Professor of Surgery, National & Kapodistrian University of Athens (NKUA), Greece
Malamatenios Markus Aurilios	Resident Gastroenterology
Marquardt Jens	Internal medicine, endocrinology, metabolic disorders, and gastroenterology, University Hospital Schleswig-Holstein Kiel
Matthaios Dimitrios	Associate Professor of Oncology, Director of the University Oncology Clinic, Democritus University of Thrace, Alexandroupoli
Moehler Marcus	Head of GI Oncology, Senior Physician Gastroenterology & Endosonography Head, Mainz University Clinic, Specialist in internal medicine, gastroenterologist, ESMO-certified oncologist
Moening Stefan	Univ.-Prof. Dr.med, Head of Upper GI Surgery, Department of Surgery University Hospital of Geneva Switzerland
Mueller Lothar	
Papaioannou Dimitrios	Pathologist
Papalois Apostolos	Head of the Education and Translational Research, HEAL Academy, Hellenic Healthcare Group, President of the Scientific Council of the Special Unit for Biomedical Research and Education, School of Medicine, Aristotle University of Thessaloniki
Papathanasiou Ilias	PhD FRCSLT ASHA Fellow Professor Department of Speech and Language Therapy, University of Patras, Patras, Greece
Papaxoinis Georgios	Medical Oncologist, «Agios Savvas» Anticancer Hospital
Pavlou Kalliopi	Pathologist MD, Msc., Athens Medical Center
Perrakis Aristotelis	Clinical Director of General, Oncology & Minimally Invasive Surgery - Liver, Pancreas, Gallbladder, Colon Center Medical Center of Athens
Petinellis Effie	Radio oncologist
Petrowski Katja	
Pipikos Theodoros	Nuclear Physician, Director of the Department of Nuclear Medicine and PET/CT, «HYGEIA» Hospital
Schizas Dimitrios	Associate Professor of Surgery, National and Kapodistrian University of Athens, «Laiko» General Hospital



FORUM ON DIGESTIVE ONCOLOGY.

GASTRIC & ESOPHAGEAL MALIGNANCIES ACROSS DISCIPLINES

10 - 11
October
2025

Venue Royal Olympic
Hotel ATHENS



FACULTY

Shmanko Kateryna	Internal medicine resident physician, University Medical Center Mainz
Sivanathan Visvakanth	MBBS, MS, MRCS(Eng), FRACS, FCSSL, General Surgeon
Sismandiou Olga	Pathologist-Oncologist, «Bioclinic» Thessaloniki
Staikou Maria	Radiologist, «Iatropolis»
Stamataki Asteria	Dietitian-Nutritionist RD ,MSc , PhDcand · Dietitian-Nutritionist PhD cand / Medical School Of Athens, MSc in Clinical Nutrition
Stamou Konstantinos	General Surgeon, Director of the Second Surgical Clinic, «MITERA»
Tegos Theodoros	MD, PhD, Pathological Oncologist, General Hospital of Athens «O Evangelismos»
Thomaidis Thomas	MD, PhD, Gastroenterologist, Associate Professor, Johannes-Gutenberg University of Mainz, Germany. Partner of the Gastroenterology Clinic, «HYGEIA» Hospital
Thuss-Patience Peter	Klinik für Innere Medizin - Hämatologie, Onkologie und Palliativmedizin Vivantes Klinikum im Friedrichshain
Triantafyllou Tania	Assistant Professor, National and Kapodistrian University of Athens
Tripodaki Elli Sofia	MD, PhD, Oncologist, Oncology Clinic, «Agioi Anargyroi» Hospital
Tzaninis Dimitrios	Medical Oncologist, Athens Medical Group
Tzimas Georgios	MD, PhD, MSc, FACS, FRCSC C, Surgeon, Director of the Department of Hepato-Pancreatic and Biliary Surgery, «HYGEIA», Assistant Professor of surgery, University Of Vermont
Vassos Nikolaos	Surgical Oncologist and Professor of Surgery at the University of Heidelberg, Germany
Veros Christos	MD, MSc Medical Oncologist, Division of Genetic Oncology, «HYGEIA» Hospital
Vogiatzis Merkourios	Nuclear Physician, Associate of the Departments of Nuclear Medicine and PET - CT, National Medical Center «HYGEIA»
Watanabe Norika	Oncologist, Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, Tokyo
Weinmann Arndt	Head of Admission Coordination and Clinical Management Senior physician in the HCC and oncology outpatient clinic Head of Clinical Registry Unit (CRU), Mainz University Clinic.



GENERAL INFORMATION

Organized by:

Hellenic Society of Gastrointestinal Oncology <https://digestiveoncology.org.gr>

In Cooperation with

Johannes Gutenberg University of Mainz <https://www.uni-mainz.de/en/>

Under the Auspices

European Society of Digestive Oncology (ESDO) <https://www.esdo.eu/>

Date:

October 10 - 11, 2025

Venue:

Royal Olympic Hotel (Panorama Hall)
28, Athanasiou Diakou str.
117 43, Athens, Greece
Tel. +30 210 9288400



Registrations:

Registration and attendance are allowed only to Health Care Professionals and undergraduate/graduate students. Registrations require presentation/proof of professional capacity or status.

Registration costs:

Registration and attendance to the Forum is free to all Health Care Professionals and undergraduate/graduate students.

Instructions for attendance:



Participants who wish to attend the Forum should have completed their registration online via the link:

<https://ets.betterevents.live/form/lypas2025>



To connect to the Conference Hall, select from the menu at the bottom of your screen, the icon "**Meeting Room**".



Note: If you wish to receive a certificate of attendance, it is necessary to visit the virtual "**Conference Secretariat**", and complete your "**Registration**" for the scientific event by clicking on the corresponding icon, so that the monitoring time starts to be recorded.



GENERAL INFORMATION

Certificate of attendance:

The certificate of attendance will be sent at the end of the event to those delegates who have completed their registration. A necessary condition for receiving the attendance certificate is the completion of at least 60% of the total hours of the scientific program.

Disclaimer: The event will be photographed, videotaped and broadcasted live.

Secretariat:



Events & Travel Solutions

154 El. Venizelou str., N. Smirni, Athens, Greece, 171 22, Tel.: +30 210 98 80 032

Website: www.events.gr E-mail: ets@events.gr

Reproduction, republishing, copying, storing, selling, transmitting, distributing, publishing, executing, downloading, translating, modifying in any manner without the express prior written consent of the Company, all or part of the Program Content is expressly prohibited. E.T.S. Events & Travel Solutions expressly reserves all of its legal right to the protection of intellectual and industrial property rights.

For more detailed information visit www.events.gr.



Organization

In cooperation with

ΕΠΕΑΕΚ

ΕΠΙΧΕΙΡΗΣΙΑΚΟ ΠΡΟΓΡΑΜΜΑ

ΕΣΠΑ

ΕΥΡΩΠΑΪΚΗ ΕΝΩΣΗ

FORUM ON DIGESTIVE ONCOLOGY.

GASTRIC & ESOPHAGEAL

MALIGNANCIES ACROSS

DISCIPLINES

10 - 11

October

2025

Venue Royal Olympic

Hotel ATHENS



SPONSORS



Bayer



BIANEE A.E.
ΒΙΟΜΗΧΑΝΙΑ ΦΑΡΜΑΚΩΝ
ΕΤΑΙΡΕΙΑ ΤΟΥ ΟΜΙΛΟΥ ΓΙΑΝΝΑΚΟΠΟΥΛΟΥ



Pierre Fabre
FARMAKA S.A.



- E.T.S. Events & Travel Solutions (2025)®

